Evaluation of neprilysin sequence variation in relation to CSF β-Amyloid levels and Alzheimer disease risk

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 1, 2010, Pages 47-52

  Blomqvist, Mia E ^a   McCarthy, Shane ^b   Blennow, Kaj ^c   Andersson, Björn ^a   Prince, Jonathan A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Simons Center for Quantitative Biology   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

amyloid; Alzheimer disease; Metalloendopeptidase; MME; Neprilysin; Polymorphism

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; MEMBRANE METALLOENDOPEPTIDASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN DEGRADATION; QUANTITATIVE TRAIT LOCUS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77953933868     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39:17-23.
2. Strittmatter WJ, Sunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977-1981.
3. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6:143-150.
4. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292:1550-1552.
5. Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol Ther 2005; 108:129-148.
6. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003; 350:113-116.
7. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
8. Morelli L, Llovera R, Gonzalez SA, Affranchino JL, Prelli F, Frangione B, Ghiso J, Castano EM. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem 2003; 278:23221-23226.
9. Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide, Neurosci Lett 2001; 297:97-100.
10. Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002; 61:849-856.
11. Li C, Booze RM, Hersh LB. Tissue-specific Expression of Rat Neutral Endopeptidase (Neprilysin) mRNAs. J Biol Chem 1995; 270:5723-5728.
12. Li C and Hersh LB. Characterization of the promoter region of the rat neprilysin gene, Arch Biochem Biophys 1998; 358: 189-195.
13. D'Adamio L, Shipp MA, Masteller EL, Reinherz EL. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5-prime untranslated regions. Proc Nat Acad Sci 1989; 86:7103-7107.
14. Clarimon J, Munoz FJ, Boada M, Tarraga L, Sunyer J, Bertranpetit J, Comas D. Possible increased risk for Alzheimer's disease associated with neprilysin gene. J Neural Transm 2003; 110:651-657.
15. Helisalmi S, Hiltunen M, Vepsalainen S, Iivonen S, Mannermaa A, Lehtovirta M, Koivisto AM, Alafuzoff I, Soininen H. Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients, J Neurol Neurosurg Psychiatry 2004; 75:1746-1748.
16. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet 2004; 114:581-587.
17. Hill WG. Estimation of linkage disequilibrium in randomly mating populations. Heredity 1974; 33:229-239.
18. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data, Am J Hum Genet 2001; 68:978-989.
19. Stephens M and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data, Am J Hum Genet 2003; 73:1162-1169.
20. Carson JA and Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002; 8:1-8.
21. Sumitomo M, Shen R, Walburg, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signalling, J Clin Invest 2000; 106:1399-1407.
22. Johnson AR, Coalson JJ, Ashton J, Larumbide M, Erdos EG. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme. Am Rev Respir Dis 1985; 132:1262-1267.
23. Balog T, Marotti T, Abramic M, Beusan-Svoboda I, Sobocanec S, Hrsak I. Neutrophil neutral endopeptidase variation and its regulation by opioid peptides. Int Immunopharmacol 2001; 1:569-579.
24. Barnes K, Turner AJ, Kenny AJ. Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry. J Neurochem 1992; 58:2088-2096.
25. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, Kanzaki A, Yamamoto M, Fujisawa Y, Okumura K, Kuroda S. Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17:164-169.
26. Lilius L, Forsell C, Axelman K, Winblad B, Graff C, Tjernberg L. No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients. Neurosci Lett 2003; 337:111-113.
27. Oda M, Morino H, Maruyama H, Terasawa H, Izumi Y, Torii T, Sasaki L, Nakamura S, Kawakami H. Dinucleotide repeat polymerphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci Lett 2002; 320:105-107.
28. Sodeyama N, Mizusawa H, Yamada M, Itoh Y, Otomo E, Matsushita M. Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes. J Neurol Neurosurg Psychiatry 2001; 71:817-818.
29. Shi J, Zhang S, Tang M, Ma C, Zhao J, Li T, Liu X, Sun Y, Guo Y, Han H, Ma Y, Zhao Z. Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons. J Gerontol A Biol Sci Med Sci 2005; 60:301-306.